Leslie Shaw to Brain
This is a "connection" page, showing publications Leslie Shaw has written about Brain.
Connection Strength
0.922
-
Duong MT, Das SR, Khandelwal P, Lyu X, Xie L, McGrew E, Dehghani N, McMillan CT, Lee EB, Shaw LM, Yushkevich PA, Wolk DA, Nasrallah IM. Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer's and Lewy body disease. Brain. 2025 May 13; 148(5):1577-1587.
Score: 0.129
-
Howard E, Irwin DJ, Rascovsky K, Nevler N, Shellikeri S, Tropea TF, Spindler M, Deik A, Chen-Plotkin A, Siderowf A, Dahodwala N, Weintraub D, Shaw LM, Trojanowski JQ, Vaishnavi SN, Wolk DA, Mechanic-Hamilton D, Morley JF, Duda JE, Grossman M, Cousins KAQ. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. Neurology. 2021 04 06; 96(14):e1855-e1864.
Score: 0.096
-
Paterson RW, Bartlett JW, Blennow K, Fox NC, Shaw LM, Trojanowski JQ, Zetterberg H, Schott JM. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry. 2014 Jul 29; 4:e419.
Score: 0.061
-
Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, Jagust W, Jack C, Reiman EM, Davatzikos C, Shaw LM, Trojanowski JQ. Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. Acta Neuropathol Commun. 2014 Mar 06; 2:26.
Score: 0.059
-
Mattsson N, Insel P, Nosheny R, Trojanowski JQ, Shaw LM, Jack CR, Tosun D, Weiner M. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging. 2014 Mar; 35(3):614-22.
Score: 0.058
-
Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JQ, Aisen P, Petersen RC, Schuff N, Weiner MW. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2012 Sep; 22(9):1993-2004.
Score: 0.051
-
Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010 Jul 13; 75(2):143-51.
Score: 0.046
-
Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009 Jul 28; 73(4):287-93.
Score: 0.043
-
Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 2009 Jul 28; 73(4):294-301.
Score: 0.043
-
Leuzy A, Bollack A, Pellegrino D, Teunissen CE, La Joie R, Rabinovici GD, Franzmeier N, Johnson K, Barkhof F, Shaw LM, Arkhipenko A, Schindler SE, Honig LS, Moscoso Rial A, Sch?ll M, Zetterberg H, Blennow K, Hansson O, Farrar G. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease. Alzheimers Dement. 2025 Mar; 21(3):e14528.
Score: 0.032
-
Rahmani M, Dierker D, Yaeger L, Saykin A, Luckett PH, Vlassenko AG, Owens C, Jafri H, Womack K, Fripp J, Xia Y, Tosun D, Benzinger TLS, Masters CL, Lee JM, Morris JC, Goyal MS, Strain JF, Kukull W, Weiner M, Burnham S, CoxDoecke TJ, Fedyashov V, Fripp J, Shishegar R, Xiong C, Marcus D, Raniga P, Li S, Aschenbrenner A, Hassenstab J, Lim YY, Maruff P, Sohrabi H, Robertson J, Markovic S, Bourgeat P, Dor? V, Mayo CJ, Mussoumzadeh P, Rowe C, Villemagne V, Bateman R, Fowler C, Li QX, Martins R, Schindler S, Shaw L, Cruchaga C, Harari O, Laws S, Porter T, O'Brien E, Perrin R, Kukull W, Bateman R, McDade E, Jack C, Morris J, Yassi N, Bourgeat P, Perrin R, Roberts B, Villemagne V, Fedyashov V, Goudey B. Evolution of white matter hyperintensity segmentation methods and implementation over the past two decades; an incomplete shift towards deep learning. Brain Imaging Behav. 2024 Oct; 18(5):1310-1322.
Score: 0.031
-
Tosun D, Hausle Z, Iwaki H, Thropp P, Lamoureux J, Lee EB, MacLeod K, McEvoy S, Nalls M, Perrin RJ, Saykin AJ, Shaw LM, Singleton AB, Lebovitz R, Weiner MW, Blauwendraat C. A cross-sectional study of a-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function. Alzheimers Dement. 2024 08; 20(8):5114-5131.
Score: 0.030
-
Brand AL, Lawler PE, Bollinger JG, Li Y, Schindler SE, Li M, Lopez S, Ovod V, Nakamura A, Shaw LM, Zetterberg H, Hansson O, Bateman RJ. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review. Alzheimers Res Ther. 2022 12 27; 14(1):195.
Score: 0.027
-
Tian C, Stewart T, Hong Z, Guo Z, Aro P, Soltys D, Pan C, Peskind ER, Zabetian CP, Shaw LM, Galasko D, Quinn JF, Shi M, Zhang J. Blood extracellular vesicles carrying synaptic function- and brain-related proteins as potential biomarkers for Alzheimer's disease. Alzheimers Dement. 2023 03; 19(3):909-923.
Score: 0.026
-
Tosun D, Demir Z, Veitch DP, Weintraub D, Aisen P, Jack CR, Jagust WJ, Petersen RC, Saykin AJ, Shaw LM, Trojanowski JQ, Weiner MW. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimers Dement. 2022 07; 18(7):1370-1382.
Score: 0.025
-
Browndyke JN, Wright MC, Yang R, Syed A, Park J, Hall A, Martucci K, Devinney MJ, Shaw L, Waligorska T, Moretti EW, Whitson HE, Cohen HJ, Mathew JP, Berger M. Perioperative neurocognitive and functional neuroimaging trajectories in older APOE4 carriers compared with non-carriers: secondary analysis of a prospective cohort study. Br J Anaesth. 2021 12; 127(6):917-928.
Score: 0.025
-
Guo T, Shaw LM, Trojanowski JQ, Jagust WJ, Landau SM. Association of CSF A?, amyloid PET, and cognition in cognitively unimpaired elderly adults. Neurology. 2020 10 13; 95(15):e2075-e2085.
Score: 0.023
-
Staffaroni AM, Cobigo Y, Goh SM, Kornak J, Bajorek L, Chiang K, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber D, Caso C, Coppola G, Dever R, Dheel C, Dickerson BC, Dickinson S, Dominguez S, Domoto-Reilly K, Faber K, Ferrall J, Fields JA, Fishman A, Fong J, Foroud T, Forsberg LK, Gavrilova R, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Heuer HW, Hsiung GY, Huey ED, Irwin DJ, Jones DT, Jones L, Kantarci K, Karydas A, Kaufer DI, Kerwin DR, Knopman DS, Kraft R, Kramer JH, Kremers WK, Kukull WA, Litvan I, Ljubenkov PA, Lucente D, Lungu C, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis SM, McKinley E, Mendez MF, Miller BL, Multani N, Onyike C, Padmanabhan J, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Rascovsky K, Roberson ED, Rogalski E, Sengdy P, Shaw LM, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski JQ, Weintraub S, Wang P, Wong B, Wszolek Z, Boxer AL, Boeve BF, Rosen HJ. Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimers Dement. 2020 01; 16(1):37-48.
Score: 0.022
-
Heuer HW, Wang P, Rascovsky K, Wolf A, Appleby B, Bove J, Bordelon Y, Brannelly P, Brushaber DE, Caso C, Coppola G, Dickerson B, Dickinson S, Domoto-Reilly K, Faber K, Ferrall J, Fields J, Fishman A, Fong J, Foroud T, Forsberg LK, Gearhart D, Ghazanfari B, Ghoshal N, Goldman J, Graff-Radford J, Graff-Radford N, Grant I, Grossman M, Haley D, Hsiung GY, Huey E, Irwin D, Jones D, Kantarci K, Karydas A, Kaufer D, Kerwin D, Knopman D, Kornak J, Kramer JH, Kraft R, Kremers WK, Kukull W, Litvan I, Ljubenkov P, Mackenzie IR, Maldonado M, Manoochehri M, McGinnis S, McKinley E, Mendez MF, Miller BL, Onyike C, Pantelyat A, Pearlman R, Petrucelli L, Potter M, Rademakers R, Ramos EM, Rankin KP, Roberson ED, Rogalski E, Sengdy P, Shaw L, Syrjanen J, Tartaglia MC, Tatton N, Taylor J, Toga A, Trojanowski J, Weintraub S, Wong B, Wszolek Z, Boeve BF, Rosen HJ, Boxer AL. Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort. Alzheimers Dement. 2020 01; 16(1):60-70.
Score: 0.022
-
Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. Lancet Neurol. 2020 01; 19(1):71-80.
Score: 0.022
-
Phillips JS, Da Re F, Irwin DJ, McMillan CT, Vaishnavi SN, Xie SX, Lee EB, Cook PA, Gee JC, Shaw LM, Trojanowski JQ, Wolk DA, Grossman M. Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer's disease. Brain. 2019 06 01; 142(6):1701-1722.
Score: 0.021
-
Albuquerque ML, Kurth CD, Monitto CL, Shaw L, Anday EK. Ethanol, morphine and barbiturate alter the hemodynamic and cerebral response to cocaine in newborn pigs. Biol Neonate. 1995; 67(6):432-40.
Score: 0.016
-
Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA. Relationships between biomarkers in aging and dementia. Neurology. 2009 Oct 13; 73(15):1193-9.
Score: 0.011